TAO WU to Esophageal Neoplasms
This is a "connection" page, showing publications TAO WU has written about Esophageal Neoplasms.
Connection Strength
0.499
-
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. Mol Cancer. 2025 Jun 11; 24(1):175.
Score: 0.172
-
HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study. Cancer Commun (Lond). 2024 Dec; 44(12):1431-1443.
Score: 0.164
-
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study. Eur J Cancer. 2024 Nov; 212:114328.
Score: 0.163